Drug (ID: DG01720) and It's Reported Resistant Information
Name
Gemcitabine/Trametinib
Synonyms
Gemcitabine/Trametinib
    Click to Show/Hide
Drug Resistance Disease(s)
Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
Pancreatic cancer [ICD-11: 2C10]
[1]
Target . NOUNIPROTAC [1]
Type(s) of Resistant Mechanism of This Drug
  UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Click to Show/Hide the Resistance Disease of This Class
Pancreatic cancer [ICD-11: 2C10]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Unusual Activation of Pro-survival Pathway (UAPP) Click to Show/Hide
Key Molecule: GTPase KRas (KRAS) [1]
Molecule Alteration Other
p.G12_G13 (c.34_39)
Resistant Disease Pancreatic ductal adenocarcinoma [ICD-11: 2C10.0]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Pancreas N.A.
Experiment for
Drug Resistance
Plasma analysis
References
Ref 1 A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreasEur J Cancer. 2014 Aug;50(12):2072-81. doi: 10.1016/j.ejca.2014.04.024. Epub 2014 Jun 7.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.